Status:
UNKNOWN
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
Annadal stichting
Conditions:
Hemochromatosis
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Hereditary Hemochromatosis (HH) is a genetic disorder of iron metabolism, resulting in excessive iron overload causing damage of different important organs like heart, liver, pancreas and joints. Comp...
Eligibility Criteria
Inclusion
- Patients with hereditary hemochromatosis (HH), homozygous for C282Y, currently treated with phlebotomy as maintenance therapy for at least 12 months with ≥ 3 phlebotomies per year.
- Ferritin level between 50-100 μg/L at start of the inclusion.
- Age: 18 years- 60 years and weight \> 50 kg.
Exclusion
- Patients receiving other therapies such as chelating therapy or forced dietary regimen.
- Patients younger than 18 years.
- HH patients with excessive overweight (BMI \> 35).
- Patients who are mentally incapacitated.
- Women being pregnant or expecting/ planning to become pregnant during the one year period of the study.
- Patients with a malignancy.
- Patients already on PPI treatment.
- Patients who experienced side effects of PPI's.
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2013
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01524757
Start Date
March 1 2012
End Date
August 1 2013
Last Update
February 2 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital Gasthuisberg
Leuven, Limburg, Belgium, 3000
2
Atrium MC Parkstad
Heerlen, Limburg, Netherlands, 6440 AG
3
Maastricht university medical center
Maastricht, Limburg, Netherlands, 6202AZ